Article · 13 May 2025
ArticlePublished 10 Feb 2025
Discriminant Analysis to Multiple Pharmaceutical New Projects: A Postulation for Cost Reduction and Competitive Advantage
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In this paper, we investigate the postulation for cost reduction and competitive advantage in the pharmaceutical companies by analysing the research and development cost in those companies, where we predict this cost to be low if such postulations are applied. We use a discriminant analysis model with linear discriminant function to predict how pharmaceutical companies will prefer their cost of research and development. Our results and analysis predict that pharmaceutical companies will prefer high research and development cost for the multiple areas of new drugs and diseases rather than low cost, and the choice is more obvious in the areas for antineoplastic drugs (cancer diseases), alimentary tract and metabolism (digestive diseases), sensory organs drugs (eyes, ears, nose, or tongue diseases), dermatologics (skin diseases), and antiinfectives (infectious diseases). We recommend future research to replicate and assure our results.
Keywords
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Journal of Biology and Today's World.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biology and Today's World
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Tamer A. Elnashar”
- BylineArticles whose byline prints “Noha T. Elnashar”
